康德萊(603987.SH):浙江康德萊擬以資本公積及留存收益轉增股本
格隆匯 6 月 22日丨康德萊(603987.SH)公佈,為增強公司全資子公司浙江康德萊醫療器械股份有限公司(以下簡稱“浙江康德萊”)的綜合競爭力,根據《公司法》和浙江康德萊《公司章程》的規定,浙江康德萊擬以資本公積及留存收益轉增股本。
增資方案:浙江康德萊醫療器械股份有限公司擬以總股份數200,000,000股為基數,以資本公積中投資者投入的資本及留存收益向全體股東同比例轉增股本,其股份數由200,000,000股增加至400,000,000股,註冊資本由人民幣200,000,000元增加至人民幣400,000,000元。
增資標的名稱:浙江康德萊醫療器械股份有限公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.